



## 4,4'-Diaponeurosporene-Producing Bacillus subtilis Increased Mouse Resistance against Salmonella typhimurium Infection in a CD36-Dependent Manner

#### Haofei Liu, Wenwen Xu, Qinghua Yu and Qian Yang\*

College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China

#### **OPEN ACCESS**

#### Edited by:

Marcello Chieppa, IRCCS "de Bellis", Italy

#### Reviewed by:

Daniele Corridoni, University of Oxford, UK Nicolas Bouladoux, National Institute of Allergy and Infectious Diseases, USA

#### \*Correspondence:

Qian Yang zxbyq@njau.edu.cn

#### Specialty section:

This article was submitted to Mucosal Immunity, a section of the journal Frontiers in Immunology

Received: 12 February 2017 Accepted: 07 April 2017 Published: 26 April 2017

#### Citation:

Liu H, Xu W, Yu Q and Yang Q (2017) 4,4'-Diaponeurosporene-Producing Bacillus subtilis Increased Mouse Resistance against Salmonella typhimurium Infection in a CD36-Dependent Manner. Front. Immunol. 8:483. doi: 10.3389/fimmu.2017.00483 Deficient mucosal innate immunity is a hallmark of infectious diarrhea, such as *Salmonella typhimurium* (*S. typhimurium*)-induced gastroenteritis. Here, we report that oral administration of a 4,4'-diaponeurosporene-producing *Bacillus subtilis* (B.s-Dia) could improve mice mucosal immunity, as showed by an increased resistance against *S. typhimurium* infection. Intragastric administration of B.s-Dia for 7 days could increase the secretion of CCL20 by intestinal epithelial cells (IECs) and then recruit more dendritic cells. Meanwhile, the number of CD8 $\alpha\alpha^+$  intraepithelial lymphocytes, which play a critical role in downregulating immune responses, was also reduced, probably as a consequence of the decrease of IEC-derived TGF $\beta$ . Further study showed that CD36 played a critical role in B.s-Dia-induced immune enhancement, as blocking CD36 signal with a specific antagonist, sulfo-N-succinimidyl oleate, led to the inability of B.s-Dia to enhance mucosal innate immunity.

#### Keywords: Bacillus subtilis, C30 carotenoid, CD36, mucosal defense, oral administration

#### INTRODUCTION

The mucosal immune system can be regarded as the first immunological barrier encountered by microorganism and, in some cases, also serves as an infection site for many pathogens (1, 2). Deficient mucosal innate immunity is a hallmark of infectious diarrhea, such as *Salmonella typhimurium*)-induced gastroenteritis (3–5). Probiotics promoted mucosal immune system development and led to development of the pre-immune antibody repertoire (6).

Carotenoids, a subfamily of the isoprenoids containing more than 700 members, are currently used for food colorants in animal feeds and nutritional supplements (7). Nutrition balances the metabolic requirements with an appropriate immune function and plays a critical role in regulating pathogen persistence at mucosal barrier (8). Carotenoids as a dietary supplement can effectively promote innate immunity (9) and are important for the prevention of many diseases (9–11). Early studies demonstrating the ability of dietary carotenes to prevent infections have left open the possibility that the action of these carotenoids may be through their prior conversion to vitamin A. Subsequent studies showed that these non-provitamin A carotenoids were as active, and at times more active, than  $\beta$ -carotene in enhancing cell-mediated and humoral immune response in animals and humans (9). However, in spite of the multiple beneficial outcomes of carotenoid supplements,

the instability and high cost make carotenoids difficult to widely apply, especially in remote area (12). Thus, an effective carotenoid and/or a suitable delivery system are urgently needed.

*Bacillus subtilis* (*B. subtilis*) is a well-known host for alkalinefermented food and have been referred to act as a probiotic in virtue of its healthy benefit for human and animals (13, 14). Recently, *B. subtilis* as oral vaccine vehicles is particularly appealing. Accumulated evidence has shown the benefits of using the non-pathogenic, spore-forming bacterium as a non-invasive and highly thermostable, safe, and low-cost vaccine delivery system (15, 16). Considering the excellent antigen delivery function of *B. subtilis*, it might also serve as a powerful tool to deliver carotenoids.

In our previous study, we achieved the production of a C30 carotenoid, 4,4'-diaponeurosporene (Dia) in *B. subtilis* and found Dia was a potent inducer of dendritic cells (DCs) maturation *in vitro* (17). Here, the major emphasis of our study has been in developing a better understanding on the immune outcomes of the 4,4'-diaponeurosporene-producing *B. subtilis* (B.s-Dia) *in vivo*. Our results indicated that intragastric administration of B.s-Dia improves mice mucosal immunity, as showed by an increased resistance against *S. typhimurium*, which is a mode pathogen of intestinal infection. Then, we further investigated the mechanism underlying B.s-Dia-induced immunoenhancement. B.s-Dia promotes intestinal epithelial cells (IECs) to release CCL20 and increased the number of lamina propria (LP) DCs. Moreover, through specific antagonist blocking we showed that CD36 was critical in this progress.

#### RESULTS

#### Dia-Treated CMT93 Cells Release Soluble Molecule to Stimulate DC Activation

Our previous study revealed the different functions of Dia from  $\beta$ -carotene on DCs (17), bringing the possibility that the different number of carbons make them act differently. Hence, we compared the influences of carotenoids with different carbon numbers (as shown in Figure 1A) on DCs. We found only Dia could induce DCs to upregulate the expression of MHCII and CD80 (Figure 1B). The upregulation of MHCII and CD80 unlikely caused by some unknown components in Dia extraction, because DCs treated with CE (extraction from B. subtilis harboring pMK3) had no changes in the expression of MHCII and CD80. In vivo, DCs are in close contact with and are governed by IECs (18). Therefore, we tested whether carotenoids could influence DCs through stimulating epithelial cells. We incubated DCs with supernatants from mouse IEC line, CMT93, which were pretreated with different carotenoids. Only supernatant from Dia-treated CMT93 increased the expression of the cell surface activation marker CD80 on DCs (Figure 1C) and the secretion of IL-6, IL-10, and IL-12p70 (Figure 1D). The results indicated a unique function of Dia on IECs and DCs.

## B.s-Dia Improved Mouse *S. typhimurium* Resistance

Before evaluating the immune function of B.s-Dia, we asked if administration of *B. subtilis* harboring control plasmid (B.s) or B.s-Dia were safe. To this end, mice were intragastrically given  $1 \times 10^9$  colony forming units (cfu) B.s or B.s-Dia every day for 1 month, and the body was weighted daily. As shown in **Figure 2A**, no significant changes were observed among different groups. Moreover, there were also no obvious pathological changes in ileum and colon as showed by hematoxylin and eosin staining (**Figure 2B**).

To test the immune function of B.s-Dia, we detected the influences of intragastric administration of B.s-Dia on mice survival when they were experimentally infected with *S. typhimurium*. Mice were intragastrically given PBS or  $1 \times 10^{\circ}$  cfu B.s or B.s-Dia every day for 7 days, followed by an experimentally infection of *S. typhimurium*. After 12 h, the number of *S. typhimurium* in mesenteric lymph nodes (MLN) was determined by plate count, and the rest of mice were retained for survival testing. As shown in **Figure 2C**, B.s-Dia administration significantly reduced the number of *S. typhimurium* diffused into MLN. Moreover, there was no survival in PBS or B.s groups on day 10 after infection, whereas 54% of mice given B.s-Dia were still alive (**Figure 2D**). These results indicated that intragastric administration of B.s-Dia improved mouse resistance against *S. typhimurium* infection.

#### Intragastric Administration of B.s-Dia Increased the Number of LP DCs and Reduced the Proportion of $CD8\alpha\alpha^+$ Intraepithelial Lymphocytes (IELs)

Dendritic cells that line the gastrointestinal tract play a key role in the establishment of both innate and adaptive immune responses (19). Gut commensal microbes shape the mucosal immune system by regulating the differentiation and expansion of DCs in LP (20, 21). To investigate the mechanisms underlying B.s-Dia-induced immune enhancement, we tested the influences of B.s-Dia on LP CD11c<sup>+</sup> cells. As shown in **Figures 3A–C**, B.s-Dia remarkably increased the number of LP CD11c<sup>+</sup> cells as well as their expression of CD36. *In vitro* study showed that B.s-Dia also had a stronger ability to induce DCs maturation compared with B.s (**Figure 3D**).

The IELs, which, by their immediate proximity to antigens in the gut lumen, form the front line of immune defense against invading pathogens (22). However, most of IELs express CD8 $\alpha$  homodimer, which is a TCR repressor, leading to a limited ability to induce immune response compared to CD8 $\alpha\beta^+$  IELs (23). B.s-Dia gavage reduced the proportion of CD8 $\alpha\alpha^+$  IELs and correspondingly increased the proportion of CD8 $\alpha\beta^+$  IELs (**Figure 3E**). Such a change might be beneficial for reducing the threshold for the activation of immune response to invading pathogens.

# B.s-Dia Enhanced CCL20 Production but Inhibited TGF $\beta$ Production

Being positioned in close proximity to a large community of commensal microbes, IECs' function is regulated by the encountered bacteria, which could be then translated into different signals, such as secretion of CCL20 and TGF $\beta$ , to the underlying immune cells (24, 25). IEC-derived CCL20 is a critical component to recruit



**FIGURE 1** | **The unique function of 4,4**'-diaponeurosporene (Dia) on dendritic cells (DCs). (A) The structural representation of geranylgeranyl pyrophosphate ammonium salt, squalene, and phytoene. (B) DCs were treated with 1µM indicated carotenoids for 24 h, and the expression of MHCII and CD80 were analyzed by flow cytometry. CE: extraction from *Bacillus subtilis* harboring pMK3. (C,D) CMT93 cells were treated with different carotenoids for 1 h, and the medium containing carotenoids were removed. After washing three times, fresh medium was added and cultured for 24 h. Then, the mediums were collected to incubate DCs. After 24 h, the expression of MHCII and CD80 on DCs were analyzed by flow cytometry (C), and the levels of IL-6, IL-10, and IL-12p70 in supernatants were detected by ELISA (D). One representative of three similar independent experiments is shown. Asterisks indicate statistical significance *via* the one-way ANOVA test (\**P* < 0.05, \*\**P* < 0.01).

intestinal DCs. To investigate the influence of B.s-Dia on CCL20 production, CMT93 cells were treated with PBS, B.s, B.s-Dia, or 1  $\mu$ M purified Dia for 1 h. After 24 h, the level of CCL20 in cultural supernatant was determined by ELISA. We found B.s-Dia or Dia greatly increased CCL20 secretion by CMT93 (**Figure 4A**). Next, we asked if B.s-Dia had a similar effect *in vivo*. As shown in **Figure 4B**, the production of CCL20 by IECs was significantly increased after B.s-Dia administration. To confirm this result, we also isolated IECs by EDTA digestion, after culturing for 6 h, a conformably increased expression of CCL20 was observed in IECs from B.s-Dia gavage mice (**Figure 4C**). Different from CCL20, the primary outcome of TGF $\beta$  signaling in the intestinal

epithelium is growth inhibition and has an important tolerogenic action on immune cells (26). B.s-Dia and Dia could reduce the production of TGF $\beta$  in CMT93 cell (**Figure 4D**). Consistently, a greatly reduced level of TGF $\beta$  was also observed in IECs from B.s-Dia gavage mice (**Figure 4E**).

Stimulation and release of pro-inflammatory cytokines are essential steps for the activation of effective innate host defense. IL-1 $\beta$ , one of the most important pro-inflammatory cytokine, contributes to host defense against infection by augmenting antimicrobial properties of phagocytes (27, 28). B.s-Dia administration did not induce the secretion of IL-1 $\beta$  on steady state; however, its production was markedly increased as soon as



6 h after *S. typhimurium* gavage (**Figure 4F**), while B.s or PBS gavage had no influence on IL-1 $\beta$  production at this time point. Our results roughly indicated that B.s-Dia might have the ability to "activate" IECs, which made them "ready" for confronting *S. typhimurium* infection.

#### CD36 Signaling Was Critical in B.s-Dia-Induced Immune Process

CD36 is abundant on the apical membrane of IECs and is capable of initiating intracellular signaling cascades that activate multiple genes, such as those encoding cytokines and co-stimulatory molecules (29, 30). Moreover, CD36 involves in the absorption of many carotenoids in small intestine (31). Our previous study showed that B.s-Dia increased the expression of CD36 on DCs (17). So, we asked whether CD36 also involved in B.s-Dia-IECs interaction. Though B.s-Dia did not colonize mice intestinal tract (Figure 5A), it could reach IECs surface as showed by microscopic examination (Figure 5B). This offered opportunities for B.s-Dia to stimulate IECs. Further investigation found that, although B.s-Dia could not enhance the expression of CD36 on CD326<sup>+</sup> IECs (Figure 5C), CD36 signaling indeed had a critical role in B.s-Dia-induced immune activation. Blocking CD36 signal with a specific antagonist, sulfo-N-succinimidyl oleate (SSO), remarkably reduced B.s-Dia-induced CCL20 expression, accompanied by a decreased number of DCs in LP (Figure 5D). The change of CCL20 production was also confirmed by ELISA (Figure 5E). Moreover, when mice were treated with SSO, B.s-Dia also lost the ability to enhance mouse resistance against S. typhimurium infection (Figure 5F). SSO alone had no influence on both *S. typhimurium* infection and IEC-derived cytokines (Figure S1 in Supplementary Material). These results together indicated the critical role of CD36 in B.s-Dia-induced immune enhancement.

#### DISCUSSION

This is the first study to explore the immunological enhancement function of a carotenoid-producing probiotics in vivo and provides a new idea to improve mucosal immunity. Jennifer et al. generated a  $\beta$ -carotene-producing variant of the probiotic Escherichia coli strain Nissle 1917, which had the ability to activate murine DCs in vitro. But, it is a pity that no in vivo experiments were performed to examine its immune functions (32). Compared with Nissle 1917, B. subtilis has many advantages, such as resistance to different environmental stresses, easily prepared and maintained, low storage costs. Here, B. subtilis was employed to serve as a factory for producing carotenoid and, at the same time, as a delivery system. Considering the lipid solubility of carotenoids (33), it might be easier for Dia to be distributed on the cell wall of B. subtilis. Indeed, in Staphylococcus aureus, most staphyloxanthin, a Dia analog, is cell wall bounded (34). Hence, the combination of Dia with B. subtilis might make it much easier for Dia to connect with enterocyte.

Epithelial cells are active participants in mucosal defense. They function as sensors that detect dangerous microbial components through pattern recognition receptors and respond by sending cytokine and chemokine signals to underlying mucosal cells, such as DCs, to trigger innate, non-specific defenses and promote adaptive immune responses (15). B.s-Dia could contact with and



forming units B.s or B.s-Dia for 7 days. (A) The frequencies of CD45<sup>+</sup> CD11c<sup>+</sup> cells in small intestinal LP cells of the indicated mice were analyzed by flow cytometry. (B) Immunostaining of small intestines from the corresponding mice in (A) was shown. (C) The expression of CD36 (green) on CD11c<sup>+</sup> cells (red) of the indicated mice was detected by confocal microscope. (D) The expression of MHCII and CD40 of CD11c<sup>+</sup> cells with the indicated treatments was detected by flow cytometry. (E) The frequencies of IELs of the indicated mice were analyzed by flow cytometry. One representative of three similar independent experiments is shown. Asterisks indicate statistical significance *via* the one-way ANOVA test (\**P* < 0.05, \*\**P* < 0.01). Scale bar, 100 µm.

activate IECs. By means of expressing bacterial adhesions on surface, *B. subtilis* is capable of binding to the gut epithelium and persist longer in gastrointestinal tract (35). More researches are needed to make sure whether a prolonged retention time is a benefit for B.s-Dia to improve mucosal immune function.

CD36 is a class B scavenger receptor that binds ligands of both pathogen and self-origin, playing an important role in innate immune response (36, 37). It is clear that, on monocytes/macrophages, CD36 functions in recognizing pathogen-associated and danger-associated molecular pattern molecules that can initiate and sustain inflammatory responses (38). Previous study showed that CD36 is a phagocytic receptor for *S. aureus* (39), and expression of CD36 in human embryonic kidney (HEK) 293T cells conferred a threefold increase in binding of *S. aureus* and a twofold increase with *E. coli* over mock-transfected control cells. In fact, our previous study showed that Dia could remarkably increase the expression of CD36 on DCs, bringing up the hint that *S. aureus*, which could synthesize Dia naturally, might increase the expression of CD36 HEK293, and then further improve the uptake of bacteria. Similarly, compared with B.s, B.s-Dia-induced expression of CD36 on DCs might make it much easier for DCs to sample B.s-Dia. This might offer B.s-Dia a relatively specific action toward DCs. Except for those expressed by DCs and macrophages, CD36 is also abundantly expressed on the apical membrane of IECs and is responsible for the uptake of low density lipoprotein and carotenoids (40, 41). Recently, Cifarelli et al. showed that deficiency of CD36 impaired small intestinal barrier (42), providing the first evidence indicating the important role of CD36 in gut immunity. Now, our finding showed CD36 signaling in IECs participated in CCL20 production, which was critical in DCs recruitment, unveiling a new function of CD36 in mucosal immunity. Previous study showed that B. subtilis increased the secretion of CCL20 by human Caco-2 cells in vitro (43), but we did not observe significant increase of CCL20 production in mouse IECs after B. subtilis gavage. These contradictory results might be due to the species differences. However, in spite of the critical role of CD36 in Dia-related immune functions, whether CD36 is a receptor for Dia still remains to be addressed.



Intragastric administration of B.s-Dia did not influence the secretion of IL-1 $\beta$  by IECs on steady state but remarkably increased its production upon S. typhimurium infection. It seemed that B.s-Dia gavage make IECs alert to S. typhimurium infection. Moreover, B.s-Dia gavage also reduced the production of TGF $\beta$  and the number of CD8 $\alpha\alpha^+$  IELs. The primary outcome of TGF<sup>β</sup> signaling in the intestinal epithelium is growth inhibition and CD8 $\alpha\alpha^+$  IELs induction (26, 44). So, the decrease of TGF $\beta$ , on the one hand, might promote epithelium growth, and on the other hand, might suppress the development of  $CD8\alpha\alpha^+$ IELs. Considering the limited ability of CD8 $\alpha\alpha^+$  IELs to induce immune response (23), its decrease might be beneficial for the defense of S. typhimurium infection. Taken together, oral administration of B.s-Dia could improve host defense against infections, at least in part through the positive regulation of IL-1 $\beta$  and the negative regulation of TGFβ-IELs axis.

In conclusion, we found the B.s-Dia could increase the expression of CCL20 by IECs and recruited more DCs in a CD36dependent manner. Moreover, it could reduce the production of TGF $\beta$  and the number of CD8 $\alpha\alpha^+$  IELs. These might make the mucosal immune system more alert to pathogenic infection and increase host defenses against *S. typhimurium* (Schematically presented in **Figure 6**). Though the potential off-target effects might exist, our findings uncovered a new method to improve innate mucosal immune system. More researches are needed to illustrate the immune function of B.s-Dia and its off-target effects in humans.

#### MATERIALS AND METHODS

#### Animals, Cells, and Bacterial Strains

C57BL/6 mice, 8 weeks old, were from the Animal Research Center of Yangzhou University (Jiangsu, China). The mice were



similar independent experiments is shown.

maintained under specific pathogen-free conditions for at least 1 week before use. CMT93 cell line (ATCC CCL223) was purchased from JINIOU company (Guangzhou, China) and cultured in RPMI 1640 supplemented with 10% fetal calf serum, 100 U/ml penicillin, and 100 U/ml streptomycin. *B. subtilis* WB800 and *S. typhimurium* SL1344 were purchased form Hangzhou Biosci Biotech Company (Hangzhou, China).

S. aureus ATCC25923 and E. coli DH5 $\alpha$  were used for genetic construction. All bacteria strains were grown in Luria–Bertani (LB) broth (10 g tryptone, 5 g yeast extract, and 5 g NaCl per liter) or on LB plates fortified with 1.5% agar at 37°C. Appropriate antibiotics were included at the following concentrations: 50 µg/ml kanamycin, 100 µg/ml ampicillin, or 500 µg/ml streptomycin.



Reagents

APC-CD11c (N418), FITC-CD40 (1C10), FITC-MHCII (M5/114.15.2), APC-CD3 (17A2), FITC-CD4 (GK1.5), PE-IL-17 (eBio17B7), PE-Foxp3 (NRRF-30), FITC-CD8 $\alpha$  (53-6.7), PE-CD8 $\beta$  (H35-17.2), PE-CD326 (G8.8), APC-CD45 (MB4B4), or respective isotype controls were from eBioscience (San Diego, CA, USA). Hamster anti-mouse CD11c (N418) monoclonal antibody (mAb), rabbit anti-mouse CCL20 (MIP-3a) polyclonal antibody, rabbit anti-mouse CD36 (MF3) mAb, and SSO were from Abcam (New Territories, Hong Kong). Dylight 488-, 594-, or 647-conjugated secondary antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Geranylgeranyl pyrophosphate ammonium salt (G6025), squalene (S3626), and phytoene (78903) were from Sigma-Aldrich (St. Louis, MO, USA).

#### **Obtainment of B.s-Dia**

To generate B.s-Dia, we structured a *B. subtilis–E. coli* shuttle vector pMK3-crtMN, which conferred *B. subtilis* the ability to produce Dia after electroporation. For more details, see Ref. (10).

#### Intragastric Administration with Bacteria

PBS,  $1 \times 10^{9}$  cfu *B. subtilis*, or *B. subtilis*-producing Dia (B.s-Dia) or equal B.s-Dia combined with 200 µg SSO were intragastrically administrated once a day for seven times, then sacrificed, and subsequent experiments were performed. For some mice,  $5 \times 10^{8}$  cfu *S. typhimurium* was administrated by gavage, and 6 h later, subsequent experiments were performed.

#### Plate Count

Mice were given PBS or  $1 \times 10^{9}$  cfu B.s or B.s-Dia every day by gavage for 7 days. On day 8, all mice were intragastrically infected with  $5 \times 10^{8}$  cfu *S. typhimurium*. After 12 h, mouse MLN were removed under aseptic condition and cut into small pieces and grinded in 1 ml PBS. The homogenates were centrifuged at  $600 \times g$  for 10 min, and the supernates were plated on LB agar

plates containing 500  $\mu g/ml$  streptomycin and cultured at 37°C for 16 h. Then, bacterial colony on the plates was counted.

### **Generation of DCs**

Dendritic cells were generated as previously reported (45). Briefly, bone marrow cells of C57BL/6 mice (4 weeks old) were flushed from the tibias and femurs and cultured in complete medium (RPMI 1640 with 10% FBS, 1% streptomycin and penicillin, 10 ng/ml GM-CSF and IL-4). On day 3, the medium was gently replaced with fresh medium. On day 6, non-adherent and loosely adherent DC aggregates were harvested and subcultured overnight. On day 7, 90% or more of the CD11c<sup>+</sup> non-adherent cells were used.

## In Vitro Culture Procedures

#### **Direct Stimulation**

Dendritic cells were treated with  $1\mu$ M Dia, geranylgeranyl pyrophosphate ammonium salt (C20), squalene (C30), phytoene (C40) or equal volume of CE for 24 h, respectively, and the expression of MHCII and CD80 on DCs were analyzed by flow cytometry.

#### Indirect Stimulation

CMT93 cells were treated with different carotenoids for 1 h, and the medium containing carotenoids were removed. After washing three times with PBS, fresh medium was added and cultured for 24 h. Then, culture supernatants were collected to incubate DCs. Another 24 h later, the expressions of MHCII and CD80 on DCs were analyzed by flow cytometry, and the levels of IL-6, IL-10, and IL-12p70 in supernatants were detected by ELISA.

# Isolation of Lamina Propria Lymphocytes (LPLs) and IELs

Lamina propria lymphocyte isolation and intracellular cytokine staining were performed as described before (46). Briefly, mice were killed and intestines removed. After removal of residual mesenteric fat tissue and Peyer's patches, the intestine was then cut into 1.5 cm pieces. The pieces were incubated twice in 5 ml of 5 mM EDTA in HBSS for 15–20 min at 37°C. Then, the epithelial cell layer was removed by intensive vortexing and passing through a 100  $\mu$ m cell strainer. The intestine was cut in 1 mm<sup>2</sup> pieces and placed in digestion solution containing 4% fetal calf serum, 0.5 mg/ml each of Collagenase D (Roche) and DNase I (Sigma), and 50 U/ml Dispase (Fisher) at 37°C for 20 min with slow rotation. After the initial 20 min, the solution was vortexed intensely and passed through a 40- $\mu$ m cell strainer. The procedure was repeated a total of three times. The supernatants were combined, washed once in cold FACS buffer, resuspended in 10 ml of the 40% fraction of a 40:80 Percoll gradient, and centrifuged for 20 min at 2,500 rpm. LPLs were collected and resuspended in FACS buffer or T cell medium. The cells were used immediately for experiments.

## Surface and Intracellular Cytokine Staining

The previously harvested cells were washed twice with cold PBS and then stained with 7AAD, followed by fluorescent mAbs staining at 4°C for 0.5 h as per the manufacturer's guidelines. After washing three times with PBS, the cells were phenotypically analyzed by FACS. For intracellular cytokine staining, the cells were incubated for 4–5 h with 50 ng/ml PMA (Sigma), 750 ng/ml ionomycin (Sigma), and 10 µg/ml brefeldin A (Invitrogen) in a cell culture incubator at 37°C. After surface staining, the cells were resuspended in fixation/permeabilization solution (BD Cytofix/ Cytoperm kit—BD Pharmingen), and intracellular cytokine staining was performed as per the manufacturer's protocol. After excluding dead cells by 7AAD, the level of IL-17 or foxp3 were analyzed with flowjo.v10.

#### Immunofluorescence and Confocal Microscopy

Fixed filters were permeabilized in 0.2% Triton X-100 in PBS for 5 min. After blocking with 5% bovine serum albumin in PBS for 1 h, the filters were incubated with the primary antibodies overnight at 4°C, followed by fluorescent secondary antibodies at room temperature for 1 h. DCs were immunolabeled with Armenian hamster anti-CD11c mAb followed by Alexa Fluor 488 or 647-conjugated goat anti-Armenian hamster IgG. CD36 were labeled with rabbit anti-mouse mAb (MF3) followed by Alexa Fluor 488-fluor 488-conjugated goat anti-rabbit IgG. The cryosections were visualized by CLSM (LSM 710, Zeiss, Oberkochen, Germany).

#### Cytokine Assays by Enzyme-Linked Immunosorbent Assay

The epithelial cell layer was digested as described above and cultured for 6 h at 37°C. The amounts of cytokines (CCL20, IL-1 $\beta$ ,

#### REFERENCES

- Oshima T, Miwa H. Gastrointestinal mucosal barrier function and diseases. J Gastroenterol (2016) 51(8):768–78. doi:10.1007/s00535-016-1207-z
- Pelaseyed T, Bergstrom JH, Gustafsson JK, Ermund A, Birchenough GM, Schutte A, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. *Immunol Rev* (2014) 260(1):8–20. doi:10.1111/imr.12182

or TGF $\beta$ ) in cultural supernatant were measured using enzymelinked immunosorbent assay (eBioscience) and performed according to the manufacturer's instructions.

### **Statistical Analysis**

Results were expressed as means  $\pm$  SD. One-way ANOVA was employed to determine statistical differences among multiple groups, and *t*-test was employed to determine the same between two groups. *P* values <0.05 were considered significant (\**P* < 0.05, \*\**P* < 0.01). Survival curves were analyzed using a Kaplan–Meier survival analysis with log-rank tests.

## **ETHICS STATEMENT**

The animal studies were approved by the Institutional Animal Care and Use Committee of Nanjing Agricultural University and followed National Institutes of Health guidelines for the performance of animal experiments.

### **AUTHOR CONTRIBUTIONS**

HL designed and performed the experiments and also wrote the manuscript; WX and Qinghua Yu contributed to the performance of the experiments; and Qian Yang designed and directed the research.

## FUNDING

This work was supported by 31372465 from the National Science Grant of China and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.00483/ full#supplementary-material.

FIGURE S1 | The influences of sulfo-N-succinimidyl oleate (SSO) on Salmonella typhimurium infection and levels of IL-1β and TGFβ secreted by IECs. (A) Mice were intragastrically administrated with PBS or 200 μg SSO daily for 7 days. On day 8, all mice were intragastrically infected with  $5 \times 10^{\circ}$ colony forming units (cfu) *S. typhimurium*. Mouse survival rate was recorded daily. Survival curves were analyzed using a Kaplan–Meier survival analysis with log-rank tests, n = 12. (B) Mice were intragastrically administrated of PBS,  $1 \times 10^{\circ}$  cfu B.s or 4,4'-diaponeurosporene-producing *Bacillus subtilis* for 7 days. The epithelial cell layer was digested and cultured for 6 h at 37°C. The amounts of cytokines IL-1β or TGFβ in cultural supernatant were measured by ELISA. Data were analyzed via one-way ANOVA test.

- Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? *Lancet* (2003) 361(9376):2226–34. doi:10.1016/S0140-6736(03)13779-8
- Thapar N, Sanderson IR. Diarrhoea in children: an interface between developing and developed countries. *Lancet* (2004) 363(9409):641–53. doi:10.1016/ S0140-6736(04)15599-2
- Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, et al. The global burden of nontyphoidal *Salmonella* gastroenteritis. *Clin Infect Dis* (2010) 50(6):882–9. doi:10.1086/650733

- Rhee KJ, Sethupathi P, Driks A, Lanning DK, Knight KL. Role of commensal bacteria in development of gut-associated lymphoid tissues and preimmune antibody repertoire. *J Immunol* (2004) 172(2):1118–24. doi:10.4049/jimmunol. 172.2.1118
- Schmidt-Dannert C. Engineering novel carotenoids in microorganisms. *Curr* Opin Biotechnol (2000) 11(3):255–61. doi:10.1016/S0958-1669(00)00093-8
- De Rosa V, Galgani M, Santopaolo M, Colamatteo A, Laccetti R, Matarese G. Nutritional control of immunity: balancing the metabolic requirements with an appropriate immune function. *Semin Immunol* (2015) 27(5):300–9. doi:10.1016/j.smim.2015.10.001
- 9. Chew BP, Park JS. Carotenoid action on the immune response. *J Nutr* (2004) 134(1):257s–61s.
- Ribaya-Mereado JD, Blumberg JB. Lutein and zeaxanthin and their potential roles in disease prevention. J Am Coll Nutr (2004) 23(6):567s–87s.
- Cooper DA. Carotenoids in health and disease: recent scientific evaluations, research recommendations and the consumer. J Nutr (2004) 134(1):221s-4s.
- Boy E, Mannar V, Pandav C, de Benoist B, Viteri F, Fontaine O, et al. Achievements, challenges, and promising new approaches in vitamin and mineral deficiency control. *Nutr Rev* (2009) 67(Suppl 1):S24–30. doi:10.1111/j.1753-4887.2009.00155.x
- Harwood CR. Bacillus subtilis and its relatives: molecular biological and industrial workhorses. Trends Biotechnol (1992) 10(7):247–56. doi:10.1016/0167-7799(92)90233-L
- Wang J, Fung DY. Alkaline-fermented foods: a review with emphasis on pidan fermentation. *Crit Rev Microbiol* (1996) 22(2):101–38. doi:10.3109/10408419609106457
- Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol (2006) 6(2):148–58. doi:10.1038/nri1777
- Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med (2005) 11(4):S45–53. doi:10.1038/nm1213
- Liu H, Xu W, Chang X, Qin T, Yin Y, Yang Q. 4,4'-diaponeurosporene, a C30 carotenoid, effectively activates dendritic cells via CD36 and NF-kappaB signaling in a ROS independent manner. *Oncotarget* (2016) 7(27):40978–91. doi:10.18632/oncotarget.9800
- Rescigno M. Dendritic cell-epithelial cell crosstalk in the gut. Immunol Rev (2014) 260(1):118–28. doi:10.1111/imr.12181
- Walsh KP, Mills KH. Dendritic cells and other innate determinants of T helper cell polarisation. *Trends Immunol* (2013) 34(11):521–30. doi:10.1016/j. it.2013.07.006
- Rescigno M, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease. J Clin Invest (2009) 119(9):2441–50. doi:10.1172/JCI39134
- Goto Y, Panea C, Nakato G, Cebula A, Lee C, Diez MG, et al. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. *Immunity* (2014) 40(4):594–607. doi:10.1016/j. immuni.2014.03.005
- Cheroutre H, Lambolez F, Mucida D. The light and dark sides of intestinal intraepithelial lymphocytes. *Nat Rev Immunol* (2011) 11(7):445–56. doi:10.1038/ nri3007
- Cheroutre H, Lambolez F. Doubting the TCR coreceptor function of CD8alphaalpha. *Immunity* (2008) 28(2):149–59. doi:10.1016/j.immuni.2008. 01.005
- Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol (2014) 14(3):141–53. doi:10.1038/ nri3608
- Goto Y, Ivanov II. Intestinal epithelial cells as mediators of the commensal-host immune crosstalk. *Immunol Cell Biol* (2013) 91(3):204–14. doi:10.1038/icb.2012.80
- Biancheri P, Giuffrida P, Docena GH, MacDonald TT, Corazza GR, Di Sabatino A. The role of transforming growth factor (TGF)-beta in modulating the immune response and fibrogenesis in the gut. *Cytokine Growth Factor Rev* (2014) 25(1):45–55. doi:10.1016/j.cytogfr.2013.11.001
- Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. *Immunity* (2009) 30(4):576–87. doi:10.1016/j.immuni.2009.02.007
- Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. IL-1beta processing in host defense: beyond the inflammasomes. *PLoS Pathog* (2010) 6(2):e1000661. doi:10.1371/journal.ppat.1000661
- Moore KJ, El Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, et al. A CD36-initiated signaling cascade mediates inflammatory effects of betaamyloid. J Biol Chem (2002) 277(49):47373–9. doi:10.1074/jbc.M208788200

- Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RLA. CD36-dependent signaling cascade is necessary for macrophage foam cell formation. *Cell Metab* (2006) 4(3):211–21. doi:10.1016/j.cmet.2006.06.007
- Reboul E. Absorption of vitamin A and carotenoids by the enterocyte: focus on transport proteins. *Nutrients* (2013) 5(9):3563–81. doi:10.3390/nu5093563
- Miller JK, Harrison MT, D'Andrea A, Endsley AN, Yin F, Kodukula K, et al. Beta-carotene biosynthesis in probiotic bacteria. *Probiotics Antimicrob Proteins* (2013) 5(2):69–80. doi:10.1007/s12602-013-9133-3
- Jomova K, Valko M. Health protective effects of carotenoids and their interactions with other biological antioxidants. *Eur J Med Chem* (2013) 70:102–10. doi:10.1016/j.ejmech.2013.09.054
- Mishra NN, Liu GY, Yeaman MR, Nast CC, Proctor RA, McKinnell J, et al. Carotenoid-related alteration of cell membrane fluidity impacts *Staphylococcus aureus* susceptibility to host defense peptides. *Antimicrob Agents Chemother* (2011) 55(2):526–31. doi:10.1128/AAC.00680-10
- Batista MT, Souza RD, Paccez JD, Luiz WB, Ferreira EL, Cavalcante RC, et al. Gut adhesive *Bacillus subtilis* spores as a platform for the mucosal delivery of antigens. *Infect Immun* (2014) 82(4):1414–23. doi:10.1128/IAI.01255-13
- Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. *Sci Signal* (2009) 2(72):re3. doi:10.1126/scisignal.272re3
- El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, et al. CD36 mediates the innate host response to beta-amyloid. *J Exp Med* (2003) 197(12):1657–66. doi:10.1084/jem.20021546
- Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng JS, Halle A, et al. CD36 ligands promote sterile inflammation through assembly of a toll-like receptor 4 and 6 heterodimer. *Nat Immunol* (2010) 11(2):155–61. doi:10.1038/ ni.1836
- Stuart LM, Deng JS, Silver JM, Takahashi K, Tseng AA, Hennessy EJ, et al. Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J Cell Biol (2005) 170(3):477–85. doi:10.1083/jcb.200501113
- Moussa M, Gouranton E, Gleize B, El Yazidi C, Niot I, Besnard P, et al. CD36 is involved in lycopene and lutein uptake by adipocytes and adipose tissue cultures. *Mol Nutr Food Res* (2011) 55(4):578–84. doi:10.1002/mnfr.201000399
- Buttet M, Poirier H, Traynard V, Gaire K, Tran TTT, Sundaresan S, et al. Deregulated lipid sensing by intestinal CD36 in diet-induced hyperinsulinemic obese mouse model. *PLoS One* (2016) 11(1):e0145626. doi:10.1371/ journal.pone.0145626
- Cifarelli V, Ivanov S, Xie Y, Son N-H, Saunders BT, Pietka TA, et al. CD36 deficiency impairs the small intestinal barrier and induces subclinical inflammation in mice. *Cell Mol Gastroenterol Hepatol* (2017) 3(1):82–98. doi:10.1016/j.jcmgh.2016.09.001
- Rimoldi M, Chieppa M, Larghi P, Vulcano M, Allavena P, Rescigno M. Monocyte-derived dendritic cells activated by bacteria or by bacteria-stimulated epithelial cells are functionally different. *Blood* (2005) 106(8):2818–26. doi:10.1182/blood-2004-11-4321
- Qiu Y, Wang WS, Xiao WD, Yang H. Role of the intestinal cytokine microenvironment in shaping the intraepithelial lymphocyte repertoire. *J Leukoc Biol* (2015) 97(5):849–57. doi:10.1189/jlb.3RU1014-465R
- 45. Yin Y, Qin T, Wang X, Lin J, Yu Q, Yang Q. CpG DNA assists the whole inactivated H9N2 influenza virus in crossing the intestinal epithelial barriers via transepithelial uptake of dendritic cell dendrites. *Mucosal Immunol* (2015) 8(4):799–814. doi:10.1038/mi.2014.110
- Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. *Cell* (2006) 126(6):1121–33. doi:10.1016/j.cell.2006.07.035

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Liu, Xu, Yu and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.